Repurposing carvacrol, cinnamaldehyde, and eugenol as potential anti-quorum sensing agents against uropathogenic Escherichia coli isolates in Alexandria, Egypt.
Carvacrol
Cinnamaldehyde
Egypt
Eugenol
Quorum sensing
Repurposing
Uropathogenic E. coli
Journal
BMC microbiology
ISSN: 1471-2180
Titre abrégé: BMC Microbiol
Pays: England
ID NLM: 100966981
Informations de publication
Date de publication:
23 10 2023
23 10 2023
Historique:
received:
23
06
2023
accepted:
11
10
2023
medline:
30
10
2023
pubmed:
24
10
2023
entrez:
23
10
2023
Statut:
epublish
Résumé
Urinary tract infections represent one of the most frequent hospital and community-acquired infections with uropathogenic Escherichia coli (UPEC) being the main causative agent. The global increase in the emergence of multidrug-resistant (MDR) UPEC necessitates exploring novel approaches. Repurposing natural products as anti-quorum sensing (QS) agents to impede bacterial virulence is gaining momentum nowadays. Hence, this study investigates the anti-QS potentials of carvacrol, cinnamaldehyde, and eugenol against E. coli isolated from urine cultures of Egyptian patients. Antibiotic susceptibility testing was performed for 67 E. coli isolates and 94% of the isolates showed MDR phenotype. The usp gene was detected using PCR and accordingly, 45% of the isolates were categorized as UPEC. Phytochemicals, at their sub-inhibitory concentrations, inhibited the swimming and twitching motilities of UPEC isolates, with eugenol showing the highest inhibitory effect. The agents hindered the biofilm-forming ability of the tested isolates, at two temperature sets, 37 and 30 °C, where eugenol succeeded in significantly inhibiting the biofilm formation by > 50% at both investigated temperatures, as compared with untreated controls. The phytochemicals were shown to downregulate the expression of the QS gene (luxS) and critical genes related to motility, asserting their anti-QS potential. Further, the combinatory activity of the phytoproducts with five antibiotics was assessed by checkerboard assay. The addition of the phytoproducts significantly reduced the minimum inhibitory concentrations of the antibiotics and generated several synergistic or partially synergistic combinations, some of which have not been previously explored. Overall, carvacrol, cinnamaldehyde, and eugenol could be repurposed as potential anti-QS agents, which preferentially reduce the QS-based communication and attenuate the cascades of gene expression, thus decreasing the production of virulence factors in UPEC, and eventually, subsiding their pathogenicity. Furthermore, the synergistic combinations of these agents with antibiotics might provide a new perspective to circumvent the side effects brought about by high antibiotic doses, thereby paving the way for overcoming antibiotic resistance.
Sections du résumé
BACKGROUND
Urinary tract infections represent one of the most frequent hospital and community-acquired infections with uropathogenic Escherichia coli (UPEC) being the main causative agent. The global increase in the emergence of multidrug-resistant (MDR) UPEC necessitates exploring novel approaches. Repurposing natural products as anti-quorum sensing (QS) agents to impede bacterial virulence is gaining momentum nowadays. Hence, this study investigates the anti-QS potentials of carvacrol, cinnamaldehyde, and eugenol against E. coli isolated from urine cultures of Egyptian patients.
RESULTS
Antibiotic susceptibility testing was performed for 67 E. coli isolates and 94% of the isolates showed MDR phenotype. The usp gene was detected using PCR and accordingly, 45% of the isolates were categorized as UPEC. Phytochemicals, at their sub-inhibitory concentrations, inhibited the swimming and twitching motilities of UPEC isolates, with eugenol showing the highest inhibitory effect. The agents hindered the biofilm-forming ability of the tested isolates, at two temperature sets, 37 and 30 °C, where eugenol succeeded in significantly inhibiting the biofilm formation by > 50% at both investigated temperatures, as compared with untreated controls. The phytochemicals were shown to downregulate the expression of the QS gene (luxS) and critical genes related to motility, asserting their anti-QS potential. Further, the combinatory activity of the phytoproducts with five antibiotics was assessed by checkerboard assay. The addition of the phytoproducts significantly reduced the minimum inhibitory concentrations of the antibiotics and generated several synergistic or partially synergistic combinations, some of which have not been previously explored.
CONCLUSIONS
Overall, carvacrol, cinnamaldehyde, and eugenol could be repurposed as potential anti-QS agents, which preferentially reduce the QS-based communication and attenuate the cascades of gene expression, thus decreasing the production of virulence factors in UPEC, and eventually, subsiding their pathogenicity. Furthermore, the synergistic combinations of these agents with antibiotics might provide a new perspective to circumvent the side effects brought about by high antibiotic doses, thereby paving the way for overcoming antibiotic resistance.
Identifiants
pubmed: 37872476
doi: 10.1186/s12866-023-03055-w
pii: 10.1186/s12866-023-03055-w
pmc: PMC10591344
doi:
Substances chimiques
carvacrol
9B1J4V995Q
Eugenol
3T8H1794QW
cinnamaldehyde
SR60A3XG0F
Anti-Bacterial Agents
0
Virulence Factors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
300Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
PLoS One. 2014 Mar 26;9(3):e93177
pubmed: 24671091
Antibiotics (Basel). 2022 Nov 13;11(11):
pubmed: 36421264
Appl Environ Microbiol. 2019 Jul 1;85(14):
pubmed: 31076428
J Antimicrob Chemother. 2021 Mar 12;76(4):909-919
pubmed: 33406232
BMC Infect Dis. 2021 Apr 17;21(1):361
pubmed: 33865334
Microorganisms. 2020 Mar 17;8(3):
pubmed: 32192182
Biomed Pharmacother. 2020 Oct;130:110606
pubmed: 32795924
Microorganisms. 2021 Apr 10;9(4):
pubmed: 33920265
Environ Microbiol. 2022 Jun;24(6):2630-2656
pubmed: 34559444
Planta Med. 2020 May;86(8):520-537
pubmed: 32325511
Antibiotics (Basel). 2020 Jul 01;9(7):
pubmed: 32630353
Antibiotics (Basel). 2020 Mar 02;9(3):
pubmed: 32131426
Int J Food Microbiol. 2015 Feb 16;195:30-9
pubmed: 25500277
Infect Drug Resist. 2021 May 24;14:1905-1920
pubmed: 34079301
Crit Rev Food Sci Nutr. 2020;60(18):3042-3053
pubmed: 31617738
Lancet Infect Dis. 2018 Dec;18(12):e379-e394
pubmed: 30292478
Front Microbiol. 2013 Mar 14;4:48
pubmed: 23504089
Antimicrob Resist Infect Control. 2018 Jan 29;7:17
pubmed: 29423192
Microb Pathog. 2020 Feb 13;142:104068
pubmed: 32061914
J Appl Microbiol. 2020 Dec;129(6):1566-1576
pubmed: 32502298
Lett Appl Microbiol. 2022 Jun;74(6):916-923
pubmed: 35152462
Sci Rep. 2016 Nov 03;6:36377
pubmed: 27808174
Curr Microbiol. 2020 May;77(5):755-761
pubmed: 31919670
Lett Appl Microbiol. 2006 Nov;43(5):489-94
pubmed: 17032221
Antibiotics (Basel). 2022 Jul 30;11(8):
pubmed: 36009900
Int J Health Sci (Qassim). 2019 Mar-Apr;13(2):48-55
pubmed: 30983946
Nat Rev Microbiol. 2020 Apr;18(4):211-226
pubmed: 32071440
Libyan J Med. 2021 Dec;16(1):1845444
pubmed: 33170767
Genes (Basel). 2022 Aug 06;13(8):
pubmed: 36011308
Lett Appl Microbiol. 2017 Mar;64(3):192-197
pubmed: 28063174
Pak J Pharm Sci. 2022 May;35(3(Special)):897-903
pubmed: 35791585
Qatar Med J. 2020 Apr 03;2020(1):9
pubmed: 32280610
Int J Pharm. 2016 Feb 10;498(1-2):23-31
pubmed: 26631640
Front Cell Infect Microbiol. 2022 Jun 15;12:899566
pubmed: 35782125
Front Microbiol. 2017 Aug 15;8:1566
pubmed: 28861072
Trop Biomed. 2019 Jun 1;36(2):559-568
pubmed: 33597418
J Food Prot. 2019 Mar;82(3):379-389
pubmed: 30785306
FEMS Microbiol Lett. 2014 May;354(2):133-41
pubmed: 24702283
Eur J Clin Microbiol Infect Dis. 2020 Sep;39(9):1687-1702
pubmed: 32328851
Antibiotics (Basel). 2021 Jul 09;10(7):
pubmed: 34356756
AIMS Microbiol. 2023 Mar 1;9(2):177-194
pubmed: 37091824
Int J Nephrol. 2012;2012:681473
pubmed: 22506110
PLoS One. 2015 Aug 06;10(8):e0134684
pubmed: 26248208
J Infect Dev Ctries. 2020 Feb 29;14(2):146-152
pubmed: 32146448
Microorganisms. 2022 Apr 23;10(5):
pubmed: 35630329
J Glob Antimicrob Resist. 2018 Sep;14:118-125
pubmed: 29581075
Microb Biotechnol. 2022 Jun;15(6):1695-1718
pubmed: 34843159
Appl Environ Microbiol. 2004 Dec;70(12):6951-6
pubmed: 15574886
Sci Rep. 2021 Jan 15;11(1):1487
pubmed: 33452275
Microorganisms. 2022 Jul 14;10(7):
pubmed: 35889146
J Antimicrob Chemother. 2003 Jul;52(1):128-31
pubmed: 12805266
FEMS Microbiol Lett. 2015 Jan;362(1):1-7
pubmed: 25790499
Arch Microbiol. 2020 Aug;202(6):1517-1527
pubmed: 32222779
J Appl Microbiol. 2017 Dec;123(6):1420-1428
pubmed: 28980415
Int J Mol Sci. 2022 Jun 29;23(13):
pubmed: 35806244